The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Co‐administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects
Open accessAbstract
Aims: The anticoagulant rivaroxaban is an oral, direct F actor X a inhibitor for the management of thromboembolic disorders. Metabolism and excretion involve cytochrome P450 3A4(CYP3A4) and 2J2(CYP2J2),CYP‐independent mechanisms, and P‐glycoprotein (P‐gp) and breast cancer resistance protein (B crp) (ABCG2). Methods: The pharmacokinetic effects of substrates or inhibitors of CYP3A4,P‐gp and B crp (ABCG2) on rivaroxaban were studied in healthy volunteers. Results: Rivaroxaban did not interact with midazolam (CYP3A4 probe substrate). Exposure to rivaroxaban when co‐administered with midazolam was slightly decreased by 11% (95% confidence interval [CI] −28%, 7%) compared with rivaroxaban alone. The following drugs moderately affected rivaroxaban exposure, but not to a clinically relevant extent: erythromycin (moderate CYP3A4/P‐gp inhibitor; 34% increase [95%CI 23%, 46%]), clarithromycin (strong CYP3A4/moderate P‐gp inhibitor; 54% increase [95%CI 44%, 64%]) and fluconazole (moderate CYP3A4, possible B crp [ABCG2] inhibitor; 42% increase [95%CI 29%, 56%]). A significant increase in rivaroxaban exposure was demonstrated with the strong CYP3A4,P‐gp/B crp (ABCG 2) inhibitors (and potential CYP2J2 inhibitors) ketoconazole (158% increase [95%CI 136%, 182%] for a 400 mg once daily dose) and ritonavir (153% increase [95%CI 134%, 174%]). Conclusions: Results suggest that rivaroxaban may be co‐administered with CYP3A4 and/or P‐gp substrates/moderate inhibitors, but not with strong combined CYP3A4,P‐gp and B crp (ABCG2) inhibitors (mainly comprising azole‐antimycotics, apart from fluconazole, and HIV protease inhibitors), which are multi‐pathway inhibitors of rivaroxaban clearance and elimination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Self-citationKubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Self-citationPERZBORN, E., STRASSBURGER, J., WILMEN, A., POHLMANN, J., ROEHRIG, S., SCHLEMMER, K.-H., & STRAUB, A. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01166.x · Cited by 590
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., & Meyer, U. A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09118-7 · Cited by 532
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein
Kirn, R. B., Wandel, C., Leake, B., Cvetkovic, M., Fromm, M. F., Dempsey, P. J., Roden, M. M., Belas, F., Chaudhary, A. K., Roden, D. M., et al. (1999) · Pharmaceutical Research · doi:10.1023/a:1018877803319 · Cited by 454
Committee for Proprietary Medicinal Products (CPMP)
Nahler, G. (2009) · Dictionary of Pharmaceutical Medicine · doi:10.1007/978-3-211-89836-9_243 · Cited by 441
Cited by
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001193 · Cited by 2,765
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.031 · Cited by 2,017
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2015) · Europace · doi:10.1093/europace/euv309 · Cited by 1,113
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation
Joglar, J. A., Chung, M. K., Armbruster, A. L., Benjamin, E. J., Chyou, J. Y., Cronin, E. M., Deswal, A., Eckhardt, L. L., Goldberger, Z. D., Gopinathannair, R., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.08.017 · Cited by 933
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace · doi:10.1093/europace/eut083 · Cited by 792
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0100-7 · Cited by 612
Self-citationHeidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht134 · Cited by 405
Chang, S.-H., Chou, I.-J., Yeh, Y.-H., Chiou, M.-J., Wen, M.-S., Kuo, C.-T., See, L.-C., & Kuo, C.-F. (2017) · JAMA · doi:10.1001/jama.2017.13883 · Cited by 394
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Marzolini, C., Kuritzkes, D. R., Marra, F., Boyle, A., Gibbons, S., Flexner, C., Pozniak, A., Boffito, M., Waters, L., Burger, D., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2646 · Cited by 262
Drug therapy in anticoagulation: which drug for which patient?
Millar, C. M., & Laffan, M. A. (2017) · Clinical Medicine · doi:10.7861/clinmedicine.17-3-233 · Cited by 11
Metadata
- Authors
- Mueck, W., Kubitza, D., & Becka, M.
- Venue
- British Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2013-08-20
- Volume
- 76
- Issue
- 3
- Pages
- 455-466
- ISSN
- 0306-5251 (ISSN-L)
- 1365-2125
- OpenAlex
- W1564607482
- Cited by
- 371
- References
- 31
- FWCI
- 27.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.